Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Gingko Bioworks Are Skyrocketing Today

By Scott Levine – Oct 14, 2021 at 4:22PM

Key Points

  • Raymond James and William Blair have both initiated coverage on the stock.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Wall Street is waxing bullishly on this synbio start-up.

What happened

Scared off from the stock after Scorpion Capital released a scathing report last week, investors are warming back up to Ginkgo Bioworks (DNA 0.51%). The catalyst for the rise today isn't just the shock of the critical report wearing off; it's favorable attention from Wall Street that's leading the bulls to click the buy button on this synthetic biology stock.

As of 2:47 p.m. EDT, shares of Gingko Bioworks are up 15.2%.

A digital rocket launches off of a smartphone.

Image source: Getty Images.

So what

While there haven't been any analyst upgrades today that are motivating investors to propel the stock higher, yesterday saw Rahul Sarugaser, an analyst at Raymond James, initiate coverage on the stock with an outperform rating and a price target of $14.50, according to According to Sarugaser, the synbio company's technology will help customers meet manufacturing needs in a wide swath of industries, including food, pharmaceuticals, and agriculture.

Raymond James, however, isn't alone in its bullish opinion of Ginkgo Bioworks. On Tuesday, William Blair also began covering the stock with an outperform rating. In a note to investors, Matt Larew, the analyst from William Blair, states that Ginkgo Bioworks has a "significant" competitive advantage over the long term.

Now what

Characterizing Ginkgo Bioworks as "a Frankenstein mash-up of the worst frauds of the last 20 years," the report from Scorpion Capital dampened the spirits last week of bulls who got in early on the synbio stock that recently went public through a special-purpose acquisition company (SPAC) deal. With analysts articulating their own optimistic opinions on the stock, however, it seems that investors' spirits are no longer dampened.

For prospective investors in the synbio start-up, it's important to keep in mind that analysts oftentimes have shorter investing horizons than the multiyear holding periods that we favor. Consequently, investors should perform their own due diligence before picking up shares instead of blindly following the bullish opinions of Wall Street.

Scott Levine owns shares of Ginkgo Bioworks Holdings, Inc. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ginkgo Bioworks Holdings, Inc. Stock Quote
Ginkgo Bioworks Holdings, Inc.
$1.99 (0.51%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.